<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:department>UNLISTED</gtr:department><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/832846D7-4618-4AF0-9A40-838ED2236D1A"><gtr:id>832846D7-4618-4AF0-9A40-838ED2236D1A</gtr:id><gtr:firstName>David</gtr:firstName><gtr:surname>Latchman</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/B3503266-26C5-4388-B835-3B426FDEADB5"><gtr:id>B3503266-26C5-4388-B835-3B426FDEADB5</gtr:id><gtr:firstName>Robert</gtr:firstName><gtr:otherNames>Justin</gtr:otherNames><gtr:surname>Harvey</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/6F3C80C5-1E93-4E7B-A050-C6C768F1632C"><gtr:id>6F3C80C5-1E93-4E7B-A050-C6C768F1632C</gtr:id><gtr:firstName>Richard</gtr:firstName><gtr:otherNames>J</gtr:otherNames><gtr:surname>Festenstein</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/B502872D-53F9-42EB-8D1E-45D7522C3D98"><gtr:id>B502872D-53F9-42EB-8D1E-45D7522C3D98</gtr:id><gtr:firstName>Nicholas</gtr:firstName><gtr:otherNames>William</gtr:otherNames><gtr:surname>Wood</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/7ADD968D-1D63-4687-B530-A7EC95C89DDF"><gtr:id>7ADD968D-1D63-4687-B530-A7EC95C89DDF</gtr:id><gtr:firstName>Sarah</gtr:firstName><gtr:otherNames>Joanna</gtr:otherNames><gtr:surname>Tabrizi</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/503DCF4F-003B-4EAE-807A-87D18743B8C9"><gtr:id>503DCF4F-003B-4EAE-807A-87D18743B8C9</gtr:id><gtr:firstName>Neil.</gtr:firstName><gtr:surname>McDonald</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/98007F9D-46DB-4C88-B0C5-F4C433AC7934"><gtr:id>98007F9D-46DB-4C88-B0C5-F4C433AC7934</gtr:id><gtr:firstName>Tamas</gtr:firstName><gtr:surname>Revesz</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0400000"><gtr:id>DF3D9F10-49C8-42B7-A6E4-731D9D3D8643</gtr:id><gtr:title>The role of Park 6 gene in Parkinson's Disease.</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0400000</gtr:grantReference><gtr:abstractText>Part of this preliminary work was funded by the Parkinson s disease society. This lay society has over 20000 members. We have spoken to the officers of the society and we would seek to communicate the rsearch findings to their membership in a form that is accessible.
UCL and UCLH trust is developing a forum for genetics in society. This initiative includes ethicists, social scientists, computer researchers as well as geneticists. One of its chief aims is to evaluate and develop protocols for dissemination of the results of genetic studies to the public as well as facilitating translation into clinical practice. The lead applicant is a key member of this initiative. 
The communication of genetic results to families is clearly of great importance. Where appropriate it is the practice in this institution to communicate any relevant results to families through the neurogenetic clinic of the national Hospital. this clinic is run by the lead applicant.</gtr:abstractText><gtr:technicalSummary>We previously identified a novel autosomal recessive Parkinson?s disease (PD) locus on chromosome 1p36 (PARK6). We have very recently shown that mutations in PINK1, a protein kinase which co-localizes to the mitochondria, are causal in PARK6. We identified missense and nonsense mutations in consanguineous European families. Subsequent sequencing of sporadic PD patients revealed a further five separate missense mutations affecting highly conserved amino acids of the kinase domain and a nonsense mutation which truncates the C-terminal regulatory region of the protein, indicating that mutations of this gene are a significant cause of PD.
For the first time we implicate a protein kinase in PD, a finding which will have important ramifications to the study of the aetio-pathogenesis of a disease which hitherto has been considered to be primarily a protein handling disorder. 
Preliminary work on the function of the protein shows that PINK1 localizes to the mitochondria, and that one of the familial missense mutations affects mitochondrial membrane potential. Furthermore, we have demonstrated direct interaction with the oncoprotein PKC and synphilin-1 (SNCAIP.) An in silico model of the protein predicts that all eight mutations would affect either kinase activity, regulation or substrate recognition. 
We have therefore placed PINK1 within the well characterised PKC signal transduction pathway and show that mutations in the gene could affect cell viability through disruption of mitochondrial integrity. Further work is now required to elucidate the upstream regulators of kinase activity. Characterisation of the kinase will facilitate identification of its downstream targets and hence the effects of the mutations on these targets. Using cellular models we will address the wider issues of the effects of the mutations on protein interactions, subcellular localisation and cell viability under stress. Creation of a mouse knockout/knockin model will allow detailed in vivo analis of the cellular as well as pathological effects of the mutations.</gtr:technicalSummary><gtr:fund><gtr:end>2009-11-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2004-12-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>1104734</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Parkinson's disease society</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>1649A254-DE20-4ED1-9C07-C993B183FB9E</gtr:id><gtr:impact>A brief lecture on outputs from research

Nil</gtr:impact><gtr:outcomeId>1ECD000E10E</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>90580</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>2011 - PUK - PhD Studentship</gtr:description><gtr:end>2014-01-02</gtr:end><gtr:fundingOrg>Parkinson's UK</gtr:fundingOrg><gtr:fundingRef>H-1006</gtr:fundingRef><gtr:id>76D030C4-13FE-4F88-9F61-6487BD736D80</gtr:id><gtr:outcomeId>jJac158goNs0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>5952982</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>2010 - WT/MRC - Wellcome Trust Strategic Award: A systematic investigation into the pathogenesis and course of Parkinson's syndrome - nwood</gtr:description><gtr:end>2015-12-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>B9CDAF23-3465-4CBA-A38E-C9FABB2DEDD5</gtr:id><gtr:outcomeId>AB61F3230180</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>292590</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>2009 - PUK - Project Grant - nwood</gtr:description><gtr:end>2011-10-02</gtr:end><gtr:fundingOrg>Parkinson's UK</gtr:fundingOrg><gtr:id>E3D58D01-18C5-47B4-8B4B-D9EF8720C26E</gtr:id><gtr:outcomeId>rujBsRiGXvB0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1543359</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>2010 - MRC - Senior Fellowship</gtr:description><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>A9631A2C-883E-4FD7-92AC-BA5ADD6D2A7A</gtr:id><gtr:outcomeId>ob8jyEnPtK80</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>357022</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>2010 - MJFF - Investigating Signaling Pathway Dysfunction Linked to LRRK2 - plewis</gtr:description><gtr:end>2011-12-02</gtr:end><gtr:fundingOrg>Michael J Fox Foundation</gtr:fundingOrg><gtr:id>92EAA179-F098-49FA-9997-8FBACBB9209A</gtr:id><gtr:outcomeId>HDykQMSXx8Z0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>30000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>2011 - AMS - Starter Grants for Clinical Lecturers - sgandhi</gtr:description><gtr:end>2013-09-02</gtr:end><gtr:fundingOrg>Academy of Medical Sciences (AMS)</gtr:fundingOrg><gtr:id>5516F84D-FCBD-4F9E-A082-1D2AB1F80B87</gtr:id><gtr:outcomeId>YAJPiiaW8yb0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>45000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>2008 - NIHR - Senior Investigator - nwood</gtr:description><gtr:end>2019-03-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>CE356259-41AF-43A8-80CC-F41BFC1F4B9C</gtr:id><gtr:outcomeId>r4iGivPYaQC0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2008-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>466500</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>UCLH/UCL Biomedical Research Centre</gtr:department><gtr:description>2009 - NIHR - UCL/UCLH Comprehensive Biomedical Centre Capital Project - nwood</gtr:description><gtr:end>2011-07-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>6F711353-80A1-4DCF-B06D-C97C39716FE7</gtr:id><gtr:outcomeId>rs6c2mdgLgN0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2009-12-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>1632CCA6-161C-4A8C-8484-5D0F66E3E4EB</gtr:id><gtr:title>A heterozygous effect for PINK1 mutations in Parkinson's disease?</gtr:title><gtr:parentPublicationTitle>Annals of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7f333a28718255f499b4e4420ba5c884"><gtr:id>7f333a28718255f499b4e4420ba5c884</gtr:id><gtr:otherNames>Abou-Sleiman PM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0364-5134</gtr:issn><gtr:outcomeId>06292E9492D</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D1EFC28E-9EBE-4C3F-A781-564002E4DDCF</gtr:id><gtr:title>PINK1 deficiency in ?-cells increases basal insulin secretion and improves glucose tolerance in mice.</gtr:title><gtr:parentPublicationTitle>Open biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/948b5c491080c769d4906f5e34a78056"><gtr:id>948b5c491080c769d4906f5e34a78056</gtr:id><gtr:otherNames>Deas E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2046-2441</gtr:issn><gtr:outcomeId>5464b7e2bd3084.99481426</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>77261023-8717-459C-9F93-F9E8767EEECC</gtr:id><gtr:title>Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study.</gtr:title><gtr:parentPublicationTitle>The Lancet. Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f59a922685f5199fdfb53d3100807996"><gtr:id>f59a922685f5199fdfb53d3100807996</gtr:id><gtr:otherNames>Healy DG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1474-4422</gtr:issn><gtr:outcomeId>C3E47FD9410</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ADE67FFE-3D43-4014-A8FB-2F67AA015A73</gtr:id><gtr:title>Transcriptional repression of p53 by parkin and impairment by mutations associated with autosomal recessive juvenile Parkinson's disease.</gtr:title><gtr:parentPublicationTitle>Nature cell biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bf0fdd89f105124501745e7bb20bd354"><gtr:id>bf0fdd89f105124501745e7bb20bd354</gtr:id><gtr:otherNames>da Costa CA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1465-7392</gtr:issn><gtr:outcomeId>C676318DCCF</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>61E32A8D-AAE7-462E-B2BB-2D7EDD2723F9</gtr:id><gtr:title>Analysis of genome-wide association studies of Alzheimer disease and of Parkinson disease to determine if these 2 diseases share a common genetic risk.</gtr:title><gtr:parentPublicationTitle>JAMA neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d14c3a9646f0da9792d2b4276c13d04a"><gtr:id>d14c3a9646f0da9792d2b4276c13d04a</gtr:id><gtr:otherNames>Moskvina V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2168-6149</gtr:issn><gtr:outcomeId>56f0036285f469.91718043</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C965ED5D-AFCF-461B-AB29-6F6DE439D129</gtr:id><gtr:title>Parkinson's disease and cancer: two wars, one front.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/81b016b620411b3da51cfd468ebe3c2a"><gtr:id>81b016b620411b3da51cfd468ebe3c2a</gtr:id><gtr:otherNames>Devine MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1474-175X</gtr:issn><gtr:outcomeId>k6SucsMNiwA</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9EACEA45-F72F-42C6-B03D-F5778AE37F4E</gtr:id><gtr:title>Characterization of PLA2G6 as a locus for dystonia-parkinsonism.</gtr:title><gtr:parentPublicationTitle>Annals of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e7e7ca46dd73dfb1e927975f9d7e0b57"><gtr:id>e7e7ca46dd73dfb1e927975f9d7e0b57</gtr:id><gtr:otherNames>Paisan-Ruiz C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0364-5134</gtr:issn><gtr:outcomeId>2A0B4F0B9D2</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7CEB6168-BF08-4354-97B1-87BE691D705B</gtr:id><gtr:title>Phosphorylation of HtrA2 by cyclin-dependent kinase-5 is important for mitochondrial function.</gtr:title><gtr:parentPublicationTitle>Cell death and differentiation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b1825a11096392cdb4a65efacbb12473"><gtr:id>b1825a11096392cdb4a65efacbb12473</gtr:id><gtr:otherNames>Fitzgerald JC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1350-9047</gtr:issn><gtr:outcomeId>nmAfcHskJXx</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EB788E05-E581-41F9-81A4-FDBD3E3F323D</gtr:id><gtr:title>Mitochondrial dysfunction triggered by loss of HtrA2 results in the activation of a brain-specific transcriptional stress response.</gtr:title><gtr:parentPublicationTitle>Cell death and differentiation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e3edc2144895ea1217098953b44b7e7f"><gtr:id>e3edc2144895ea1217098953b44b7e7f</gtr:id><gtr:otherNames>Moisoi N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1350-9047</gtr:issn><gtr:outcomeId>51C6C155D84</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8F1E4C08-B7C5-4F3B-A485-0D6BCCA6A273</gtr:id><gtr:title>PINK1 cleavage at position A103 by the mitochondrial protease PARL.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/948b5c491080c769d4906f5e34a78056"><gtr:id>948b5c491080c769d4906f5e34a78056</gtr:id><gtr:otherNames>Deas E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>5DA162DD_35DA162DD_3</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FD221127-76D6-4B20-8C07-0FE3FFDBDC80</gtr:id><gtr:title>Parkinson's disease in GTP cyclohydrolase 1 mutation carriers.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8ed0f28b35d5e4240d5af6d917b092bf"><gtr:id>8ed0f28b35d5e4240d5af6d917b092bf</gtr:id><gtr:otherNames>Mencacci NE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>5464b7e2ec89d4.85211994</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>013BAF8E-A17F-43EF-8416-E4F07C552518</gtr:id><gtr:title>Genome-wide association study reveals genetic risk underlying Parkinson's disease.</gtr:title><gtr:parentPublicationTitle>Nature genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/73f2f0764dd1bcc79b805b94497f0c43"><gtr:id>73f2f0764dd1bcc79b805b94497f0c43</gtr:id><gtr:otherNames>Sim?n-S?nchez J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1061-4036</gtr:issn><gtr:outcomeId>ED9F484B5ED</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A2B68498-9947-44D6-A1AE-14676ACE8CEE</gtr:id><gtr:title>The mitochondrial protease HtrA2 is regulated by Parkinson's disease-associated kinase PINK1.</gtr:title><gtr:parentPublicationTitle>Nature cell biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d1a768ac0348b89871dc88cb7217499f"><gtr:id>d1a768ac0348b89871dc88cb7217499f</gtr:id><gtr:otherNames>Plun-Favreau H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1465-7392</gtr:issn><gtr:outcomeId>002E39705F9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0FD30285-2157-45BB-9863-2435FA3BCA18</gtr:id><gtr:title>PINK1 is necessary for long term survival and mitochondrial function in human dopaminergic neurons.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/af3137ae30d800bbf896d7631ffa4d13"><gtr:id>af3137ae30d800bbf896d7631ffa4d13</gtr:id><gtr:otherNames>Wood-Kaczmar A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>7F613D4CA67</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0F97D1CE-F854-450B-B04E-285FBBAE3E61</gtr:id><gtr:title>PINK1-associated Parkinson's disease is caused by neuronal vulnerability to calcium-induced cell death.</gtr:title><gtr:parentPublicationTitle>Molecular cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7fe26393ce1a826c37d2c03b54270978"><gtr:id>7fe26393ce1a826c37d2c03b54270978</gtr:id><gtr:otherNames>Gandhi S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1097-2765</gtr:issn><gtr:outcomeId>34CB1065A02</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8DAC2F76-8778-44A0-88E2-B9E086EC15E7</gtr:id><gtr:title>Alpha-Synuclein Oligomers Interact with Metal Ions to Induce Oxidative Stress and Neuronal Death in Parkinson's Disease.</gtr:title><gtr:parentPublicationTitle>Antioxidants &amp; redox signaling</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/948b5c491080c769d4906f5e34a78056"><gtr:id>948b5c491080c769d4906f5e34a78056</gtr:id><gtr:otherNames>Deas E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1523-0864</gtr:issn><gtr:outcomeId>56f003611bf1b7.56108101</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E4408E12-7912-4653-AA5B-C4F3EABD3355</gtr:id><gtr:title>Cell metabolism affects selective vulnerability in PINK1-associated Parkinson's disease.</gtr:title><gtr:parentPublicationTitle>Journal of cell science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/521f8366c59ab87c062c9c49a518c4b8"><gtr:id>521f8366c59ab87c062c9c49a518c4b8</gtr:id><gtr:otherNames>Yao Z</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0021-9533</gtr:issn><gtr:outcomeId>pm_16517_27_22223879</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>54AEE741-7914-45AA-8FE0-865D8CEB2437</gtr:id><gtr:title>Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/63287787bb1e52ffdd058b4cf58d8780"><gtr:id>63287787bb1e52ffdd058b4cf58d8780</gtr:id><gtr:otherNames>Neumann J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>6B9444569B4</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>15EC972D-9467-4B82-AF92-A31B416BC6F0</gtr:id><gtr:title>Hyperexcitable substantia nigra dopamine neurons in PINK1- and HtrA2/Omi-deficient mice.</gtr:title><gtr:parentPublicationTitle>Journal of neurophysiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c6f617d73d5718ae5f7d8b84c2cea297"><gtr:id>c6f617d73d5718ae5f7d8b84c2cea297</gtr:id><gtr:otherNames>Bishop MW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0022-3077</gtr:issn><gtr:outcomeId>fzMfsqta1AX</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1E496D0F-166A-40AF-B80B-02AEA9A1D557</gtr:id><gtr:title>Deletions at 22q11.2 in idiopathic Parkinson's disease: a combined analysis of genome-wide association data.</gtr:title><gtr:parentPublicationTitle>The Lancet. Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cc6be3b3e5ee776d6c6cd87eccb0be6f"><gtr:id>cc6be3b3e5ee776d6c6cd87eccb0be6f</gtr:id><gtr:otherNames>Mok KY</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1474-4422</gtr:issn><gtr:outcomeId>5889d4fc200573.20473026</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2D027751-DA84-4EDE-8D82-D3FFCA8CA8E3</gtr:id><gtr:title>Signalling properties of inorganic polyphosphate in the mammalian brain.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c12f39f0c4d126b0ff8f01c4a69a02c4"><gtr:id>c12f39f0c4d126b0ff8f01c4a69a02c4</gtr:id><gtr:otherNames>Holmstr?m KM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>pm_16517_27_23322050</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>373A99C7-DE90-45AC-A796-BC8B78935F09</gtr:id><gtr:title>Understanding the molecular causes of Parkinson's disease.</gtr:title><gtr:parentPublicationTitle>Trends in molecular medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/af3137ae30d800bbf896d7631ffa4d13"><gtr:id>af3137ae30d800bbf896d7631ffa4d13</gtr:id><gtr:otherNames>Wood-Kaczmar A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1471-4914</gtr:issn><gtr:outcomeId>C3B3E997A4F</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>22DE1DE6-023A-46FB-A4C8-C535B186C864</gtr:id><gtr:title>Mitochondrial function and morphology are impaired in parkin-mutant fibroblasts.</gtr:title><gtr:parentPublicationTitle>Annals of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cf1a18a9f27248abf01877cc9a789f16"><gtr:id>cf1a18a9f27248abf01877cc9a789f16</gtr:id><gtr:otherNames>Mortiboys H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0364-5134</gtr:issn><gtr:outcomeId>7C401324BEA</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0400000</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>